A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.

Trial Profile

A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs GSK 732461 (Primary) ; Chloroquine
  • Indications HIV infections; Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms EARLY-CLINRES-004
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Sep 2014 New source identified and integrated (European Clinical Trials database record:EudraCT2009-012223-29)
    • 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Planned number of patients changed from 66 to 150 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top